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Vaso-occlusion is a determinant for most signs and symptoms of sickle-cell anemia (SCA). The mechanisms
involved in the pathogenesis of vascular complications in SCA remain unclear. It is known that genetic poly-
morphisms associated with thrombophilia may be potential modifiers of clinical features of SCA. The genetic
polymorphisms C677T and A1298C relating to the enzyme methylenetetrahydrofolate reductase (MTHFR), a
clotting Factor V Leiden mutation (1691G/A substitution of Factor V Leiden), and the mutant prothrombin
20210A allele were analyzed in this study. The aim was to find possible correlations with vascular complications
and thrombophilia markers in a group of SCA patients in Pernambuco, Brazil. The study included 277 SCA
patients, divided into two groups: one consisting of 177 nonconsanguineous SCA patients who presented
vascular manifestations of stroke, avascular necrosis, leg ulcers, priapism, and acute chest syndrome (group 1);
and the other consisting of 100 SCA patients without any reported vascular complication (group 2). Molecular
tests were done using either polymerase chain reaction (PCR) restriction fragment length polymorphism or
allele-specific PCR techniques. Comparisons between the groups were made using the v2 test. The 677 CT and
TT genotypes showed a significant risk of vascular complications ( p = 0.015). No significant associations be-
tween the groups were found when samples were analyzed for the MTHFR A1298C allele ( p = 0.913), Factor V
G1691 ( p = 0.555), or prothrombin G20210A mutation ( p = 1.000). The polymorphism MTHFR C677T seemed
to be possibly predictive for the development of some vascular complications in SCA patients among this
population.
Introduction
Sickle-cell anemia (SCA) is a monogenic disorder de-rived from a single point mutation, a substitution (GAG/
GTG) at position six of the b-globin gene located in chromo-
some 11. However, it presents a multigenic phenotype with
several complications, and different modulators dictate the
individual variations of the disease. Some contributing factors
for this phenotypic variability are already well established,
such as the coexistence of a thalassemia, b-globin gene hap-
lotypes, and Hb F levels. Unfortunately, none of them are able
to clarify the different phenotypic expression observed in
patients (Nagel and Steinberg, 2001; Steinberg, 2005).
In Brazil, the bS gene distribution is very heterogeneous,
ranging from 2% to 10%, following the proportion of African
descendants in the different geographical regions of
the country. For instance, the frequency of the bS gene in the
general population of Pernambuco, a state located in the
northeastern region of Brazil, is 4% (Cançado and Jesus, 2007).
Patients with SCA in Pernambuco tend to have a severe
clinical course, poor prognosis, and frequent hospitalizations
due to vaso-occlusive crises and higher mortality among
children in their first year of life. In this state, 79.2% of SCA
patients are homozygous for the Central African Republic bS
haplotype, which has been associated with low levels of Hb F
and clinical features of greater severity (Steinberg, 2005; Be-
zerra et al., 2007). Acute chest syndrome (ACS), avascular
necrosis (AVN) of the femoral head, leg ulcers, stroke, and
priapism are the most frequent and important vascular com-
plications in our patients.
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Adhesion of sickle cells to the endothelium plays a very
important role in vaso-occlusion phenomena. These are the
determining physiopathological events that cause most of the
signs and symptoms of sickle-cell disease (Frenette and At-
weh, 2007; Kaul et al., 2009).
Thrombosis is also an important aspect of the clinical
spectrum of sickle-cell disease. Hemostatic abnormalities
have been observed in SCA patients, such as reduced levels of
natural anticoagulant inhibitors and increased thrombin
production, platelet activation, and circulating tissue factor
levels. In summary, almost all procoagulant or anticoagulant
components become altered in sickle-cell disease. These
findings show that the steady state of sickle-cell disease is a
hypercoagulable state (Bayazit and Kilinç, 2001; Ataga and
Orringer, 2003; Al-Absi et al., 2006; Akinyoola et al., 2008).
Genetic mutations have been identified as a cause of
thrombophilia in different populations. The molecular basis
for hereditary thrombophilia includes mutations in Factor V,
prothrombin, and the methylenetetrahydrofolate reductase
(MTHFR) gene (Slavik et al., 2009).
The C677T variant of the MTHFR gene has been correlated
with a 50% decrease in the activity of the key enzyme in homo-
cysteine (Hcy) metabolism (MTHFR) and consequent increases
in plasma Hcy levels, which may cause damage to endothelial
cells. A second MTHFR polymorphism (A1298C) results in
mildly decreased MTHFR activity, but does not elevate plasma
Hcy (Al-Absi et al., 2006). Hyperhomocysteinemia is considered
to be a risk factor for several thrombotic events, including the
cerebral and peripheral types, as well as coronary disease (En-
gbersen et al., 1995; Khan and Dickerman, 2006). However, there
are several studies providing evidence that the mutations
G1691A on Factor V and G20210A on the prothrombin gene are
associated with an elevated risk of deep vein thrombosis and
with the main causes of hereditary thrombophilia (Kordes et al.,
2002; Khan and Dickerman, 2006; Ercan et al., 2008).
Because of the evidence of increased activation of the co-
agulation system in SCA, it is important to evaluate the role of
genetic variants relating to thrombophilia in vascular com-
plications of SCA. The aim of this study was thus to investi-
gate possible associations of the MTHFR variants C677T and
A1298C, Factor V Leiden mutation, and prothrombin muta-
tion with vascular complications in sickle-cell disease.
Patients and Methods
Sample
Two hundred seventy-seven patients with Hb SS and Hb
Sb0 thalassemia were enrolled for this study. The patients
were divided in two groups. Group 1 consisted of 177 non-
consanguineous SCA patients who had important vascular
complications such as stroke, AVN, leg ulcers, priapism, and
ACS. These conditions were confirmed by means of tran-
scranial Doppler and X-rays, and the clinical records of ACS
and priapism were taken from patients’ medical files. Group 2
consisted of 100 nonconsanguineous adult SCA patients
without previous stroke, AVN, leg ulcers, priapism, or ACS.
Patients on hydroxyurea and chronic transfusion therapy were
not included in this group, as their use would have a protective
effect against vascular complications (Orah and Platt, 2008).
This study was approved by the Research Ethics Commit-
tee of HEMOPE, and an informed consent statement was
signed by each study participant.
Methods
The sickle-cell disease was diagnosed by means of high-
performance liquid chromatography (Bio Rad, Hercules, CA).
DNA was extracted from peripheral blood leukocytes using the
phenol–chloroform technique (Lahiri and Nurnberger, 1991).
The MTHFR C677T polymorphism was detected by means
of polymerase chain reaction (PCR) restriction fragment
length polymorphism, using the forward primer 5¢-TGAAG
GAGAAGGTGTCTGCGG-3¢ and the reverse primer 5¢-AG
GACGGTGCGGTGAGAGTG-3¢. The C/T transition creates
a restriction site for the HinfI enzyme, and the digested
product was isolated through gel electrophoresis in 3% aga-
rose prepared with ethidium bromide. The fragments were
viewed under UV light (Frosst et al., 1995). The homozygote
for the wild-type allele (CC) produces a 198-bp fragment; the
heterozygote (CT) produces 198-, 175-, and 23-bp fragments;
and the mutant homozygote (TT) produces 175- and 23-bp
fragments. The MTHFR A1298C polymorphism was detected
by means of allele-specific PCR, using primers for separate
amplification of the wild-type and mutant alleles (allele A:
forward 5¢-GGAGCTGACCAGTGAAGA-3¢ and reverse 5¢-
TGTGACCATTCCGGTTTG-3¢ amplified a 77-bp fragment;
allele C: forward 5¢-CTTTGGGGAGCTGAAGGA-3¢ and re-
verse 5¢-AAGACTTCAAAGACACTTG-3¢ amplified a 120-bp
fragment) (Biselli et al., 2008).
Factor V Leiden mutation G1691A was detected through
amplification of exon 10 of the Factor V gene, by means of
PCR with the forward primer 5¢-CTTGAAGGAAATGCCC
CATTA-3¢ and the reverse primer 5¢-TGCCCAGTGCTTAA
CAAGACCA-3¢, followed by digestion of the PCR product
using MnlI endonuclease (Andrade et al., 1998). The G20210A
fragment on the mutant prothrombin gene was amplified
through PCR using primers as described by Poort et al. (1996),
with 5¢-TCTAGAAACAGTTGCCTGGC-3¢ as the forward
primer, and 5¢-ATAGCACTGGGAGCATTGAAGC-3¢ as the
reverse primer. The amplified 345-bp fragment was digested
using HindIII endonuclease, giving a 322-bp fragment in the
presence of the mutant allele (20210A). The HindIII- and MnlI-
digested products were viewed under UV light by means of
electrophoresis on 3% agarose gels (Andrade et al., 1998). The
products from digestion of the G20210A region of the mutant
prothrombin gene and the G1691A region of the Factor V gene
were separated through electrophoresis on 3% agarose gels,
and were then prepared using ethidium bromide and viewed
under UV light (Arsov et al., 2006).
Statistical analysis
The v2 test was first used to evaluate whether the groups
were in the Hardy–Weinberg equilibrium. Fisher’s exact test
and the v2 test were used for genotype and allele frequency
comparisons. The risk was defined in terms of odds ratios
(ORs) with confidence intervals (CIs), with significance levels
up to 95%. In all statistical evaluations, p < 0.05 was consid-
ered significant. Software STATA/SE 9.0 and Microsoft
Office Excel (2007) were used for data analysis.
Results
Among the 277 patients studied, 124 (44.7%) were female,
and 153 (55.2%) were male; 262 (94.6%) had Hb SS and 15
(5.4%) had Sb0 thalassemia. Out of the 177 patients in the
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group 1, who presented some form of vascular manifestation,
170 had a diagnosis of Hb SS and seven Sb0 of thalassemia; out
of the 100 patients in the group 2, 92 were diagnosed with Hb
SS and eight with Sb0 thalassemia. The clinical characteristics,
age, and sex distribution observed in the two both groups can
be seen in Table 1. The frequency of male patients was higher
in the group 1 than in the group 2 ( p = 0.0119; OR 1.913).
The genotype distributions in the group 1 ( p = 0.7704) and
in the group 2 ( p = 0.9537) were found to be in the Hardy–
Weinberg equilibrium. The frequency of the MTHFR 677T
allele was higher in the group 1 (50.8%) than in the group 2
(35.0%), and this difference was statistically significant
( p = 0.015; OR 1.9212; CI: 1.1587–3.1855) (Table 2), but when
each complication is considered separately and on groups of
one, two, and three complications and compared with the
group 2 (without complications), no significant association
with the MTHFR C677T polymorphism was observed
(Table 3).
Analysis on the MTHFR C677T and MTHFR A1298C hap-
lotype distribution showed higher frequency of the double
mutant 677T/1298C in the group 1 patients (26; 15.2%) than in
the group 2 (9; 9.1%), but without statistical significance
( p = 0.1920). The MTHFR A1298C, prothrombin mutation
G20210A, and Factor V Leiden mutation analysis did not
show any association with vascular complications, even when
each complication was separately considered or on groups of
one, two, and three complications. Homozygous mutations
for Factor V Leiden and mutant prothrombin were not de-
tected in any of samples (Table 2).
Molecular analysis on all of the 277 patients with sickle-cell
disease showed that five patients (1.80%) had the heterozy-
gous genotype for the G20210A prothrombin mutation, and
three patients (1.08%) had the heterozygous form for the
G1691A Factor V Leiden mutation. There were 15 patients
(5.41%) with the homozygous form (TT) for the MTHFR
C677T polymorphism, as well as 110 patients (39.7%) with the
heterozygous form (CT), such that the total prevalence of the
677T allele was 45.1%. MTHFR A1298C polymorphism anal-
ysis was performed on 269 patients, and there were 11 pa-
tients (4.0%) with the homozygote genotype for the mutant
allele, as well as 99 (36.8%) with the heterozygote genotype.
Thus, the frequency of the 1298C mutant allele was 40.9%.
Discussion
The Hematology Hospital of the HEMOPE Foundation is
the reference institution for diagnosis and treatment of sickle-
cell disease in Pernambuco; around 1800 patients are cur-
rently being followed up. Priapism, AVN, stroke, leg ulcers,
and ACS are frequently found manifestations in patients at-
tended at HEMOPE, and thus there is a great need for studies
on these complications in this region. Identification of genetic
variants that may be associated with vaso-occlusion is im-
portant for better understanding of this complex condition.
The present study ascertained that the difference between
the observed frequencies of the MTHFR 677T allele in the
group 1 (50.8%) and the group 2 (35.0%) was statistically
significant ( p = 0.015). Therefore, the MTHFR C677T poly-
morphism can be considered to be a likely predisposing factor
for the development of vascular complications among the
Table 1. Demographic Characteristics
and Distribution of Different Types of Vascular
Complications Found in Sickle-Cell Disease Patients
Group 1 Group 2
Number of patients 177 (63.9%) 100 (36.1%)
Mean age in years
(with range)
26.5 (5–72) 26.2 (18–58)
Sex
Male 108 (61.0%) 45 (45%)
Female 69 (39.0%) 55 (55%)
Vascular complications:
Stroke 45 (25.4%) N
AVN 43 (24.3%) N
ACS 31 (17.5%) N
Priapism 34 (31.5%)a N
Leg ulcers 67 (37.8%) N
Combined complications 43 (24.3%)b N
N, no vascular complications.
a31.5% of males presented priapism.
bFour cases associated between vascular complications and
thrombosis.
ACS, acute chest syndrome; AVN, avascular necrosis.
Table 2. Associations Presented by MTHFR C677T, MTHFR A1298C, Factor V Leiden,
and Prothrombin G20210A with the Risk of Vascular Complications in Sickle -Cell Disease
Genotype Group 1 (%) Group 2 (%) OR 95% CI p
MTHFR 677 n = 177 n = 100
CC 87 (49.1%) 65 (65.0%) 1 Reference 0.015a
CT/TT 90 (50.8%) 35 (35.0%) 1.9212 1.1587–3.1855
MTHFR 1298 n = 171 n = 98
AA 102 (59.6%) 57 (58.1%) 1 Reference 0.913a
AC/CC 69 (40.3%) 41 (41.8%) 0.9405 0.5679–1.5574
Factor V Leiden n = 177 n = 100
GG 174 (98.3%) 100 (100%) — — 0.555b
GA 3 (1.69%) 0 (0%) — —
Mutant prothrombin n = 177 n = 100
GG 174 (98.3%) 98 (98.0%) 1 Reference 1.000b
GA 3 (1.69%) 2 (2.00%) 0.8448 0.1388–5.1431
aw2 test.
bFisher exact test.
MTHFR, methylenetetrahydrofolate reductase; CI, confidence interval; OR, odds ratio.
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sickle-cell disease patients studied. A similar result was found
by Moreira Neto et al., when studying 53 SCD patients (HbSS
and HbSC) in southeastern Brazil. They found greater pres-
ence of the MTHFR 677T allele among SCA patients who
presented vascular complications (Moreira Neto et al., 2006).
Kutlar et al. found a statistically significant association be-
tween the MTHFR C677T polymorphism and AVN among
American patients with SCA. They found that the frequency
of the 677T allele in patients diagnosed with AVN was 35.6%,
whereas it was 12.9% for this mutation in patients not pre-
senting the complication ( p = 0.006). These authors suggested
that this polymorphism could be a possible predisposing factor
for this vascular problem (Kutlar et al., 2001). These results
contradicted what had been found in previous studies, such as
the ones by Andrade et al. in Brazil and Zimmerman and Ware
in the United States. Neither of these studies found any asso-
ciation between the MTHFR C677T polymorphism and vascu-
lar complications in SCA cases (Andrade et al., 1998;
Zimmerman and Ware, 1998). However, these studies were
performed with small samples. Adekile studied sickle-cell dis-
ease patients (HbSS and Sb thalassemia) in Kuwait, and also did
not ascertain any association. This author suggested that a lar-
ger number of patients would be needed to confirm the result
(Adekile, 2001). A more recent study by Al-Saqladi et al. on 102
children (HbSS) in Yemen did not find any association between
the MTHFR C677T polymorphism and the severity of the dis-
ease. However, the frequency of this polymorphism has been
found to be quite low in most populations (7.35%) (Al-Saqladi
et al., 2010). In our study, we also analyzed separately the vas-
cular complications: stroke, AVN, ACS, priapism, leg ulcers,
and groups of one, two, and three complications, and we did
not find a significant association with the MTHFR C677T
polymorphism. We suggested this could be happen because of
the small number of samples when they are divided.
The presence of the 677T allele is associated with increased
plasma Hcy levels, and this increase is a risk that was previ-
ously established by vessel thrombosis and arteriosclerosis
(Slavik et al., 2009). Hcy levels were not evaluated in our
study, but Lowenthal et al. showed that the plasma Hcy levels
in SCA patients were significantly higher than in healthy
control patients. This was somewhat unexpected, since sickle-
cell patients make continuous use of folic acid to improve their
erythropoiesis, and the increased folate intake induces a de-
crease in plasma Hcy levels (Lowenthal et al., 2000). In the
study by van der Djis et al. (1998), sickle-cell patients who used
oral folic acid had subclinical folate levels compared with
control patients diagnosed with Hb AA.
It is likely that the folate levels necessary for normalization
of the plasma Hcy levels in SCA patients are higher than in
healthy people, since these patients have a higher nutritional
folic acid need than seen in the general population. In the
present study, it was observed that patients carrying the 677T
allele presented a higher risk of vascular complications, and
these patients probably need even greater folate oral supple-
mentation, because of the presence of the allele.
The MTHFR A1298C polymorphism has previously been
associated with cardiovascular disease, kidney disease, spina
bifida, and hypercoagulability disorders, including stroke
(Volcik et al., 2000; Haviv et al., 2002). Our sickle-cell dis-
ease patient population showed a frequency of 40.9% for the
MTHFR 1298C allele. Robien and Ulrich (2003) described the
prevalence of MTHFR A1298C within different populations
around the world: the frequency of the C allele varies from
32% to 34% in Asia and from 46% to 62% in Eastern Europe,
and in Africans, a frequency of 38.5% has been found. Al-Absi
et al. (2006) compared 106 SCA patients with healthy controls
in Bahrain, and found a frequency of 62% for MTHFR 1298C,
which was higher in patients than in controls (47%).
This is the first study to investigate the MTHFR A1298C
polymorphism and vascular complications in sickle-cell dis-
ease. However, the presence of the mutant allele did not
present a risk of vascular complications from the disease
( p = 0.913). Even when we analyzed the combination of
MTHFR A1298C and MTHFR C677T, comparing the groups 1
and 2, there was no statistical significance ( p = 0.1920). The
MTHFR C677T single-nucleotide polymorphism is located in
exon 4 of the MTHFR gene and results in a thermolabile
protein with decreased enzymatic activity, whereas the
MTHFR A1298C polymorphism occurs in a regulatory region
of the MTHFR enzyme (exon 7) and is associated with de-
creased enzyme activity, but not with thermolability (Castro
et al., 2004; Reeves et al., 2009).
Factor V Leiden and mutant prothrombin are considered to
be the main hereditary risk factors for venous thrombosis
(Fawaz et al., 2004). The relative risk of venous thrombosis
increases threefold to eightfold and twofold to threefold, re-
spectively (Poort et al., 1996; Ramos et al., 2006). However,
these mutations were not considered to be risk factors for
vascular complications from sickle-cell disease in the present
study, and this result is in accordance with other studies in the
literature (Andrade et al., 1998; Ramos et al., 2006).
The frequency of heterozygous genotypes for Factor V
Leiden in Israelis, Arabs, Canadians, and Indians ranges from
1% to 8.5%, and some European studies have reported fre-
quencies of 5% to 8%. However, the prevalences found in
Greece, Sweden, and Lebanon have been much higher,
reaching up to 15% in some areas. On the other hand, the
mutation is rare in black Africans and apparently not present
in Chinese and Japanese people (Ridker et al., 1998). In our
study population, a frequency of 1.08% was found for the
Factor V Leiden G1691A mutation, a low frequency, similar to
afro-descendants. Arruda et al. (1997) found a similar preva-
lence of this mutation (2%) in a Brazilian population.
Table 3. Vascular Complications Acute Chest
Syndrome, Stroke, Avascular Necrosis, Leg Ulcers,
Priapism, and Combined Complications
Associated with the MTHFR C677T
MTHFR 677
CC CT/TT
n (%) n (%) p
Vascular complications
Stroke 26 (57.8) 19 (42.2) 0.518
AVN 22 (51.2) 21 (48.8) 0.171
ACS 15 (48.4) 16 (51.6) 0.148
Priapism 12 (35.3) 22 (64.7) 0.098
Leg ulcers 34 (50.7) 33 (49.3) 0.094
Combined complications
No complications 65 (65.0) 35 (35.0) 0.058
1 complication 67 (48.9) 70 (51.1)
2 complications 18 (48.6) 19 (51.4)
3 complications 2 (66.7) 1 (33.3)
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A study conducted in 11 centers in Europe found preva-
lences of the prothrombin G20210A mutation of 0.7% to 4%.
Similarly to Factor V Leiden, this mutation has been found to
be extremely rare in nonwhite populations (black or Asian
people) (Zivelin et al., 1998). In our study, we found a prev-
alence of 1.80% for the prothrombin G20210A mutation.
Because of the low frequency within any given population,
the exact mechanism for Factor V Leiden and mutant pro-
thrombin as risk factors for vascular complications in SCA pa-
tients can only be clarified through studies with higher numbers
of patients in different populations around the world.
In this study, we found that the MTHFR C677T polymor-
phism was associated with the development of vascular
complications in sickle-cell disease. Our results are in agree-
ment with previous studies in southeastern Brazil and the
United States (Kutlar et al., 2001; Moreira Neto et al., 2006), but
not with studies in other regions of Brazil and elsewhere in the
world (Andrade et al., 1998; Zimmerman and Ware, 1998;
Adekile, 2001). This is possibly because of the different genetic
compositions of these populations. In Brazil, divergent results
may occur because of the high degree of racial miscegenation
in our population.
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